P

Pulike Biological Engineering Inc
SSE:603566

Watchlist Manager
Pulike Biological Engineering Inc
SSE:603566
Watchlist
Price: 13.15 CNY 2.02% Market Closed
Market Cap: 4.5B CNY
Have any thoughts about
Pulike Biological Engineering Inc?
Write Note

Pulike Biological Engineering Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Pulike Biological Engineering Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
P
Pulike Biological Engineering Inc
SSE:603566
Accrued Liabilities
ÂĄ37.5m
CAGR 3-Years
26%
CAGR 5-Years
27%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Accrued Liabilities
ÂĄ2B
CAGR 3-Years
2%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Accrued Liabilities
ÂĄ620.1m
CAGR 3-Years
8%
CAGR 5-Years
39%
CAGR 10-Years
35%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Accrued Liabilities
ÂĄ128.5m
CAGR 3-Years
456%
CAGR 5-Years
130%
CAGR 10-Years
63%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Accrued Liabilities
ÂĄ1.5B
CAGR 3-Years
48%
CAGR 5-Years
46%
CAGR 10-Years
59%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Accrued Liabilities
ÂĄ146m
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Pulike Biological Engineering Inc
Glance View

Market Cap
4.5B CNY
Industry
Pharmaceuticals

Pulike Biological Engineering, Inc. engages in the research, development, manufacturing and sale of biological products for animals, chemical drugs and Chinese veterinary drugs. The company is headquartered in Luoyang, Henan and currently employs 1,809 full-time employees. The company went IPO on 2015-05-18. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The firm's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.

Intrinsic Value
20.5 CNY
Undervaluation 36%
Intrinsic Value
Price
P

See Also

What is Pulike Biological Engineering Inc's Accrued Liabilities?
Accrued Liabilities
37.5m CNY

Based on the financial report for Sep 30, 2024, Pulike Biological Engineering Inc's Accrued Liabilities amounts to 37.5m CNY.

What is Pulike Biological Engineering Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
27%

Over the last year, the Accrued Liabilities growth was 41%. The average annual Accrued Liabilities growth rates for Pulike Biological Engineering Inc have been 26% over the past three years , 27% over the past five years .

Back to Top